H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (United States) publishes no comparable price on its own website for cancer treatment. We found none of the four terms on its site (guarantee, redo policy, aftercare at home, named doctor). Checked 14 Nov 2026.
Facts reported from this provider's own pages, with the date we checked.
Figures are converted to Canadian dollars for comparison only. The clinic charges in the currency it publishes; your bank's rate and card fees will differ.
Published positions
Status of each term on the provider's own page: Published Partly Not stated By enquiry
Cancer treatment in the United States
Prices with one fact not stated shown as the clinic publishes them; kept out of the medians, «from» prices and cheapest-clinic lines until the clinic states the missing fact
| Procedure and scope | Published price | ≈ CAD | Guarantee | Redo | Named doctor | Aftercare | Checked |
|---|---|---|---|---|---|---|---|
AXICABTAGENE CILOLEUCEL (YESCARTA)product entry | 686,125discountedCurrency not stated | — | Not stated | Not stated | Not stated | Not stated | 14 Nov 2026source ↗ |
BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMAproduct entry | 629,475discountedCurrency not stated | — | Not stated | Not stated | Not stated | Not stated | 14 Nov 2026source ↗ |
IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSEtherapeutic dose | 680,202discountedCurrency not stated | — | Not stated | Not stated | Not stated | Not stated | 14 Nov 2026source ↗ |
About this clinic
- Where: United States
- Checking the doctor: how to check a doctor in the United States
Details
Cancer treatment in the United States
checked 6 days ago3 positions
| AXICABTAGENE CILOLEUCEL (YESCARTA) product entry | 686,125 — currency not stated discounted |
| BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMA product entry | 629,475 — currency not stated discounted |
| IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSE therapeutic dose | 680,202 — currency not stated discounted |
Included, as published
- AXICABTAGENE CILOLEUCEL (YESCARTA): not stated
- BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMA: not stated
- IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSE: not stated
Not included, as published
- Not stated on the page
- Written guarantee
- Not stated
- Revision policy
- Not stated
- Named treating doctor
- Not stated
- After you return home
- Not stated
Appears on
Is this your clinic? Correct or add to what we show — free, with your name and the date.
Is this your clinic? A free badge for your website that links to this page.